Jump to content



Celiac.com Sponsor (A1):



Celiac.com Sponsor (A1-m):


  • You've found your Celiac Tribe! Join our like-minded, private community and share your story, get encouragement and connect with others.

    💬

    • Sign In
    • Sign Up
  • Scott Adams
    Scott Adams

    Gut Microbiota Changes and Immune Dysfunction Reflect Disease Severity in Covid-19 Patients

    Reviewed and edited by a celiac disease expert.

    Gut microbiota composition and dysfunctional immune responses reflect the severity of disease in Covid-19 patients.

    Gut Microbiota Changes and Immune Dysfunction Reflect Disease Severity in Covid-19 Patients - Image: CC BY-SA 2.0--Loco Steve
    Caption: Image: CC BY-SA 2.0--Loco Steve

    Celiac.com 03/01/2021 - Although COVID-19 mainly affects the respiratory system, growing evidence indicates that the GI tract also plays a role in the disease. A team of researchers recently set out to determine if the gut microbiome is connected to disease severity in patients with Covid-19, and whether changes in microbiome composition might return to normal with the clearance of the SARS-CoV-2 virus. Here's what they found.

    The research team included Yun Kit Yeoh; Tao Zuo; Grace Chung-Yan Lui; Fen Zhang; Qin Liu; Amy YL Li; Arthur CK Chung; Chun Pan Cheung; Eugene YK Tso; Kitty SC Fung; Veronica Chan; Lowell Ling; Gavin Joynt; David Shu-Cheong Hui; Kai Ming Chow, Susanna So Shan Ng; Timothy Chun-Man Li; Rita WY Ng; Terry CF Yip; Grace Lai-Hung Wong; Francis KL Chan; Chun Kwok Wong; Paul KS Chan; and Siew C Ng.



    Celiac.com Sponsor (A12):






    Celiac.com Sponsor (A12-m):




    For their study, the team reviewed blood, stool and data from 100 patients with laboratory-confirmed SARS-CoV-2 infection. They collected serial stool samples from 27 of the 100 patients up to 30 days after clearance of SARS-CoV-2.  To assess gut microbiome compositions, they shotgun sequenced total DNA extracted from stools. They measured concentrations of inflammatory cytokines and blood markers from plasma.

    Compared with non-Covid-19 individuals. Patients with COVID-19 showed substantially changed gut microbiome composition, with or without taking medication. Several gut bacteria with known immunomodulatory potential, such as Faecalibacterium prausnitzii, Eubacterium rectale and bifidobacteria, were significantly reduced in patients and remained low for up to a month after Covid-19 resolution. 

    This altered gut microbiome displayed stratification with disease severity via elevated concentrations of inflammatory cytokines and blood markers such as C reactive protein, lactate dehydrogenase, aspartate aminotransferase and gamma-glutamyl transferase.

    The connections between gut microbiota levels, cytokines and inflammatory markers in Covid-19 patients indicate that the gut microbiome plays a significant role in Covid-19 severity possibly by modulating host immune responses. 

    The researchers suggest that gut microbiota imbalance after Covid-19 resolution could contribute to ongoing symptoms, making it important to determine the role of gut microorganisms in inflammation and Covid-19.

    Read more in Gut.

     

    The researchers are variously affiliated with the Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong; the Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; the Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong; the State Key Laboratory for digestive disease, Institute of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong; the Stanley Ho Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; the Department of Medicine and Geriatrics, United Christian Hospital, Kwun Tong, Hong Kong; the Department of Pathology, United Christian Hospital, Kwun Tong, Hong Kong; the Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Shatin, Hong Kong; the Department of Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong; and the Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong.

    Edited by Scott Adams



    User Feedback

    Recommended Comments

    Scott,

    Good article!  I Believe it!

    See this older research about how changing "Fat" bugs in our GI tract to "Skinny" Bugs people lost weight even without a Gastric Bypass necessary.

    Entitled "Gut Bacteria May Be Key to Gastric Bypass' Effects: Study"

    Quoting from the article...

    "Even when they did not perform the surgery, and just transferred the new bacterial colony into the intestines of mice, those mice lost weight." "Simply by colonizing mice with the altered microbial community, the mice were able to maintain a lower body fat, and lose weight".....

    quoting again....

    "Our study suggests that the specific effects of gastric bypass on the microbiota contribute to its ability to cause weight loss, and that finding ways to manipulate microbial populations to mimic those effects could become a valuable new tool to address obesity," senior study author Lee Kaplan, director of the Obesity, Metabolism and Nutrition Institute at Massachusetts General, said in a statement.
    "The ability to achieve even some of these effects without surgery would give us an entirely new way to treat the critical problem of obesity, one that could help patients unable or unwilling to have surgery,"

    But good luck trying to convenience anyone getting ready for a Gastric Bypass....that they have "Bad Bugs".....causing their obesity....

    FMT's have been used successfully to treat C. Diff

    https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/fecal-transplant-what-you-should-know

    Who knows in a few years they might find the difference between good health and bad heath is only our "Good" or "Bad" bugs triggering unchecked inflammation in the body.

    I hope this is helpful but it is not medical advice.

    Posterboy,

    Link to comment
    Share on other sites


    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Restore formatting

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • About Me

    Scott Adams

    Scott Adams was diagnosed with celiac disease in 1994, and, due to the nearly total lack of information available at that time, was forced to become an expert on the disease in order to recover. In 1995 he launched the site that later became Celiac.com to help as many people as possible with celiac disease get diagnosed so they can begin to live happy, healthy gluten-free lives.  He is co-author of the book Cereal Killers, and founder and publisher of the (formerly paper) newsletter Journal of Gluten Sensitivity. In 1998 he founded The Gluten-Free Mall which he sold in 2014. Celiac.com does not sell any products, and is 100% advertiser supported.


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-m):




  • Related Articles

    Scott Adams
    Celiac.com 04/30/2020 - Patients with inflammatory bowel disease (IBD) seem to suffer milder effects in the disease phase of COVID-19 than other patients, according to two new reports. That may be due to their treatment with immunosuppressant drugs, including salicylates. What's going on? Could people with celiac disease share a similar benefit?
    Because many patients with IBD receive immunosuppressive drugs, doctors have wondered whether those patients might be more susceptible to COVID-19, or its effects. On the other hand, immunomodulatory therapies might also suppress the hyperinflammatory cytokine response associated with the most severe presentations of COVID-19.
    Dr. Lorenzo Norsa and colleagues observed 522 IBD patients in their clinic at the Papa Giovanni XXIII Hospital in Bergamo, Italy, which was the epicenter of Italy’s outbreak, and suffered some of the highest rates of SARS-CoV-2 infection in the world. All of these patients are on some form of immunosuppressive drug, and more than 60% are being treated only with salicylates.
    During the observation period, the team saw no cases of COVID-19 in this group, and none of the 522 IBD patients were hospitalized with SARS-CoV-2 infection. However, during the same period, 479 patients with no IBD history were hospitalized for severe COVID-19 and respiratory failure.
    Based on the team’s calculations using data from the Wuhan region, however, there should have been 21 cases among their IBD patients. The team advised all of their IBD patients to continue their treatments as directed. 
    The team notes that immunosuppressive drug therapy did not emerge as a risk factor in earlier outbreaks of SARS and MERS coronavirus, and no patients with IBD as the only risk factor contracted serious SARS or MERS-related disease.
    These findings are fascinating. Could immunosuppressant drugs provide some protection against Covid-19? Could IBD itself offer some protection? If the protective effect is real, and due to the drug treatments, then it is unlikely people with celiac disease would get a similar benefit. Still, so many questions arise.
    Confirmation of these findings could provide some useful insight into the nature of the coronavirus, and may offer a useful tool for treating IBD patients during the Covid-19 pandemic. The team is calling for further study of the issue.
    Read more in Gastroenterology and bmj.com
     


    Scott Adams
    Celiac.com 06/15/2020 - Usually, when a food manufacturer makes an ingredient change, even a minor one, to a food product, they must produce a new label for all the changed products. However, Covid-19 has changed that. Responding to calls from food manufacturers facing supply chain problems in the wake of the Covid-19 pandemic, the Food and Drug Administration (FDA) is relaxing some labeling requirements for certain ingredients in food in the U.S.
    The move will give food manufacturers the ability make small changes to the ingredients in a product without making label changes. That may mean adding, omitting, or blending ingredients to meet the product needs.
    The FDA guidance on the matter states that such labeling changes "should not cause any adverse health effect, including those from gluten and food allergens."
    The guidance states that ingredients used as substitutes should not alter any voluntary nutrient or health claim on the label, such as gluten free, and that ingredients that are the reason for the label should not be changed.
    Basically, “Manufacturers should avoid substitutions that could result in a safety concern without making a conforming label change or providing other means to inform consumers of the change,” the new guidance says. The FDA wants to avoid any risk of allergic reaction due to any such substitutions, and the temporary rule change reflects that.
    The safety, claims, and prominence section of the guidance specifically states that no gluten ingredient can be used as a substitute for a gluten-free ingredient. The flexibility in labeling will continue for the duration of the public health emergency declared by the Department of Health and Human Services, including extensions. 
    The FDA notes that it may consider extensions, depending on how quickly supply chains return to normal.
    For questions, answers, and more information, read the FDA's page on Food Safety and the Coronavirus Disease 2019 (COVID-19) 


    Scott Adams
    Celiac.com 11/23/2020 - Since March 2020, when the World Health Organization declared coronavirus disease-2019 (COVID-19) a global pandemic, researchers and laypeople have been wondering if people with certain health conditions, such as celiac disease, might face a higher risk for contracting Covid-19. 
    Celiac disease is a chronic immune-mediated gastrointestinal condition triggered by gluten, which numerous studies have shown to be associated with an elevated risk of respiratory infection. 
    A team of researchers recently set out to determine whether celiac disease patients have a higher risk of contracting COVID-19. The research team included Jamie Zhen, Juan Pablo Stefanolo, Maria de la Paz Temprano, Sebastian Tedesco, Caroline Seiler, Alberto Fernandez Caminero, Enrique de-Madaria, Miguel Montoro Huguet, Santiago Vivas, Sonia Isabel Niveloni, Premysl Bercik, Edgardo Smecuol, Luis Uscanga, Elena Trucco, Virginia Lopez, Carolina Olano, Pasquale Mansueto, Antonio Carroccio, Peter H. R. Green, Andrew Day, Jason Tye-Din, Julio Cesar Bai, Carolina Ciacci, Elena Verdu, Benjamin Lebwohl, and Maria Ines Pinto-Sanchez.
    At this writing, the world has seen over 34 million cases of COVID-19, and more than 1 million deaths worldwide. The United States has seen over 11 million cases of Covid-19, and 250,000 deaths, with rising numbers and no end in sight. 
    The research team carried out a cross-sectional study to determine whether patients with self-reported celiac disease have an increased risk of contracting COVID-19. 
    Between March and June 2020, the team used local celiac disease associations, electronic newsletters, and social media to recruit patients of all ages with a self-reported celiac disease, and non-celiacs, from different countries including Argentina, Australia, Canada, Italy, Mexico, New Zealand, Spain, Uruguay, and the United States.  For the study, the volunteers answered forty-one questions in a web-based survey that was available in English, Spanish and Italian using the approach proposed by Mallinckrodt and Wang. 
    The researchers used RedCap to gather data on demographics, gluten-free diet (GFD), symptomatology, and COVID-19 testing. They used SPSS version 25 (IBM, Armonk, NY) for statistical analyses, and then compared continuous and categorical variables using the Mann-Whitney U test and chi-square test. They also performed logistic regression to gauge the influence of various factors on the likelihood of reporting a positive COVID-19 test. 
    Independent variables included celiac disease diagnosis, age, gender, comorbidities, gluten-free diet adherence, extra precautions, and previous COVID-19 exposure. The unadjusted and adjusted odds ratios showed 95% confidence intervals. 
    People with celiac disease tend to have more comorbidities including respiratory, cardiac, and diabetes,  compared with control subjects. Patients with celiac disease were significantly less likely to have been tested for, and to have been exposed to, COVID-19, compared with control subjects. Just under 9% of of 940 participants tested for positive for COVID-19. 
    Overall, celiac patients do not face any higher risk of contracting Covid-19 than control subjects. This analysis should provide some assurance to people with celiac disease and to clinicians that patients with celiac disease have about the same likelihood of contracting Covid-19 as the general population. However, this study did not look at whether people who have celiac disease have worse outcomes than those who do have it, and unfortunately there is some evidence that indicates that this may be the case.
    With Covid-19 cases higher than ever and rising, we encourage everyone to take precautions and be safe.
    Read more in the Clinical Gastroenterology and Hepatology
     
    The researchers are variously affiliated with the Farncombe Family Digestive Health Research Institute, McMaster University Medical Center, Hamilton Health Sciences, Hamilton, Ontario, Canada; the Hospital Dr C B Udaondo, Buenos Aires, Argentina; Alicante University General Hospital, Alicante, Spain; ||Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain; Hospital Universitario San Jorge, Huesca, Spain; University Hospital of León, Leon, Spain; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Universidad de la Republica, Montevideo, Uruguay; University of Palermo, Palermo, Italy; Columbia University, New York, New York; Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand; Walter and Eliza Hall Institute and University of Melbourne, Melbourne, Australia; and the Università degli Studi di Salerno, Salerno, Italy.


    Scott Adams
    Celiac.com 02/23/2021 - People with celiac disease face a higher risk for developing pneumococcal pneumonia, and certain types of viral infections. Because of this, many people with celiac disease have wondered if they may have a higher risk of developing Covid-19, or of developing complications or severe Covid-19-related outcomes, if they do get it. The question was serious enough for a team of researchers to take a close look at the data to see whether people with celiac disease face an increased risk of hospitalization for Covid-19, intensive care unit admission, and/or death from Covid-19.
    The research team included Benjamin Lebwohl, Emma Larsson, Jonas Söderling, Bjorn Roelstraete, Joseph A Murray, Peter HR Green, and Jonas F Ludvigsson. They are variously affiliated with the Celiac Disease Center, Department of Medicine, Columbia University Medical Center, New York, NY, USA; the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; the Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden;  the Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden;  the Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; and the Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden.
    To get the answers they needed, the team put together a population-based group study from data gathered by 28 Swedish pathology departments from 1969-2017. They first identified nearly 41,000 patients with celiac disease, defined as small intestinal villus atrophy, who were still alive on February 1, 2020. 
    They then compared data for these patients against data for nearly 184,000 controls matched by sex, age, county, and calendar period. 
    Using Cox proportional hazards with follow-up through July 31, 2020, they first assessed risk of hospital admission with a primary diagnosis of laboratory-confirmed Covid-19. They then assessed risk of a Covid-19 admission to intensive care unit and/or death attributed to Covid-19.
    They found that the overall risk of hospital admission for Covid-19 was 2.9 and 2.2 per 1000 person-years respectively. 
    After adjusting for comorbidities, they found no significantly higher risk of hospitalization for Covid-19, or of severe Covid-19, among celiac patients.
    Lastly, they saw no significant difference in mortality between celiac patients and control subjects who were hospitalized with Covid-19.
    From this data, the team concludes that people with celiac disease are not at higher risk of hospitalization for Covid-19, or for Covid-19- related intensive care admission and/or death.
    Read more at DovePress.com
     


  • Popular Now

×
×
  • Create New...